Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells

Cancer Letters

Volumn 297, Issue 2, 2010, Pages 226-230

  Takizawa, Itsuhiro ^a   Nishiyama, Tsutomu ^a   Hara, Noboru ^a   Hoshii, Tatsuhiko ^a   Ishizaki, Fumio ^a   Miyashiro, Yoshimichi ^b   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Grelan Pharmaceutical Co   (Japan)

Author keywords

3 Hydroxysteroid dehydrogenase; Agonistic activity; Androgen receptor; Prostate cancer; Trilostane

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; BICALUTAMIDE; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRILOSTANE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ENZYME INHIBITOR;

ANDROGEN METABOLISM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL ACTIVITY; CELL STRAIN LNCAP; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE MUTATION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; WILD TYPE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

3-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; HUMANS; MALE; MASS SPECTROMETRY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE;

EID: 77956439247     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.015     Document Type: Article

References (24)

1. Nishiyama T., Hashimoto Y., Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin. Cancer Res. 2004, 10:7121-7126.
2. Labrie F., Belanger A., Luu-The V., Labrie C., Simard J., Cusan L., Gomez J., Candas B. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr. Rev. 2005, 26:361-379.
3. Labrie F., Belanger A., Dupont A., Luu-The V., Simard J., Labrie C. Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med. 1993, 16:475-492.
4. Hammond G.L. Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. J. Endocrinol. 1978, 78:7-19.
5. Belanger B., Belanger A., Labrie F., Dupont A., Cusan L., Monfette G., plasma Comparison of residual C-19 steroids in, human prostatic tissue of rat and guinea pig after castration: unique importance of extratesticular androgens in men. J. Steroid Biochem. 1989, 32:695-698.
6. Geller J., Albert J.D. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urol. Res. 1987, 15:151-153.
7. Harris W.P., Mostaghel E.A., Nelson P.S., Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol. 2009, 6:76-85.
8. Friedlander T.W., Ryan C.J. Novel hormonal approaches in prostate cancer. Curr. Oncol. Rep. 2009, 11:227-234.
9. Labrie F., Luu-The V., Lin S.X., Simard J., Labrie C. Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab. 2000, 11:421-427.
10. Nakada T., Kazama T., Koike H., Yoshikawa M., Ishikawa S., Katayama T. Primary aldosteronism treated by trilostane (3 beta-hydroxysteroid dehydrogenase inhibitor). Urology 1985, 25:207-214.
11. Chu P.S., Buzdar A.U., Hortobagyi G.N. Trilostane and hydrocortisone in treatment of metastatic breast cancer. Breast Cancer Res. 1989, 13:117-121.
12. Puddefoot J.R., Barker S., Vinson G.P. Trilostane in advanced breast cancer. Expert Opin. Pharmacother. 2006, 7:2413-2419.
13. Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van Rooij H.C., Trapman J., Brinkmann A.O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 1990, 173:534-540.
14. Korenchuk S., Lehr J.E., MClean L., Lee Y.G., Whitney S., Vessella R., Lin D.L., Pienta K.J. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001, 15:163-168.
15. Sasano H., Suzuki T., Miki Y., Moriya T. Intracrinology of estrogens and androgens in breast carcinoma. J. Steroid Biochem. Mol. Biol. 2008, 108:181-185.
16. Labrie F., Luu-The V., Labrie C., Belanger A., Simard J., Lin S.X., Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 2003, 24:152-182.
17. Labrie F., Belanger A., Simard J., Luu-The V., Labrie C. DHEA and peripheral androgen and estrogen formation: intracinology. Ann. NY Acad. Sci. 1995, 774:16-28.
18. Lacoste D., Bélanger A., Labrie F. Biosynthesis and degradation of androgens in human prostatic cancer cell lines. Ann. NY Acad. Sci. 1990, 595:389-391.
19. Geldof A.A., Dijkstra I., Newling D.W., Rao B.R. Inhibition of 3 beta-hydroxysteroid-dehydrogenase: an approach for prostate cancer treatment?. Anticancer Res. 1995, 15:1349-1354.
20. Potts G.O., Creange J.E., Hardomg H.R., Schane H.P. Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 1978, 32:257-267.
21. Barker S., Malouitre S.D., Glover H.R., Puddefoot J.R., Vinson G.P. Comparison of effects of 4-hydroxy tamoxifen and trilostane on oestrogen-regulated gene expression in MCF-7 cells: up-regulation of oestrogen receptor beta. J. Steroid. Biochem. Mol. Biol. 2006, 100:141-151.
22. Williams C.J., Barley V.L., Blackledge G.R., Rowland C.G., Tyrrell C.J., Bachelot F., Dermaille A., Fargeot P., Namer M., Pouillart J., Serin D. Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Clin. Oncol. 1995, 7:87-92.
23. Puddefoot J.R., Barker S., Glover H.R., Malouitre S.D., Vinson G.P. Non-competitive steroid inhibition of oestrogen receptor functions. Int. J. Cancer 2002, 101:17-22.
24. Ingle J.N., Krook J.E., Schaid D.J., Everson L.K., Mailliard J.A., Long H.J., McCormack G.W. Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and prior hormonal therapy exposure. Am. J. Clin. Oncol. 1990, 13:93-97.